HYPERPHOSPHATEMIA PATIENTS ON HEMODIALYSIS
Clinical trials for HYPERPHOSPHATEMIA PATIENTS ON HEMODIALYSIS explained in plain language.
Never miss a new study
Get alerted when new HYPERPHOSPHATEMIA PATIENTS ON HEMODIALYSIS trials appear
Sign up with your email to follow new studies for HYPERPHOSPHATEMIA PATIENTS ON HEMODIALYSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to tame dangerous phosphate levels in dialysis patients
Disease control Recruiting nowThis study tests a new drug called TS-172 in 30 adults on hemodialysis who have high phosphate levels. Participants take the drug daily for a period, and researchers check if their phosphate levels drop to a target range. The goal is to see if TS-172 can help control phosphate, a…
Matched conditions: HYPERPHOSPHATEMIA PATIENTS ON HEMODIALYSIS
Phase: PHASE3 • Sponsor: Taisho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for dialysis patients: drug targets dangerous phosphorus levels
Disease control Recruiting nowThis study tests an experimental drug called TS-172 in 100 adults on hemodialysis who have high phosphorus levels. Participants will take TS-172 or a placebo alongside their usual phosphate binders. The goal is to see if TS-172 helps more patients reach safe phosphorus levels, wh…
Matched conditions: HYPERPHOSPHATEMIA PATIENTS ON HEMODIALYSIS
Phase: PHASE3 • Sponsor: Taisho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill aims to tame dangerous phosphate in kidney patients
Disease control Recruiting nowThis phase 3 study tests a new drug called TS-172 in 300 adults on hemodialysis who have high phosphate levels. Participants take the pill daily for up to a year to see if it safely and effectively controls phosphate. The goal is to offer a better treatment option for a common co…
Matched conditions: HYPERPHOSPHATEMIA PATIENTS ON HEMODIALYSIS
Phase: PHASE3 • Sponsor: Taisho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC